Plain-English translation of NCT06242795 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether 7% hypertonic saline—a salt water solution you inhale through a nebulizer—can help people with non-cystic fibrosis bronchiectasis clear mucus from their lungs more easily. Bronchiectasis is a condition where parts of your airways become permanently enlarged and damaged, making it hard to clear the thick mucus that builds up. Researchers want to see if this medication improves how well your lungs can move and clear that mucus.
People with bronchiectasis struggle with chronic cough and mucus buildup, which can lead to infections and breathing problems. This medication has shown promise in other lung conditions, and doctors want to understand whether this treatment could help bronchiectasis patients breathe easier and have better quality of life.
You likely qualify if…
You likely don't qualify if…
You will attend up to 5 study visits over about 4–5 weeks. At your first visit, you'll have a screening test to make sure the salt water inhalation is safe for you. Over the next two weeks, you'll use the medication twice a day as part of your regular airway clearance routine at home. Researchers will measure how well your lungs can clear mucus and check your breathing and quality of life before, during, and after the two-week treatment period using scans, breathing tests, and questionnaires.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
United States